Previous close | 12.13 |
Open | 11.93 |
Bid | 11.66 x 1000 |
Ask | 12.39 x 1300 |
Day's range | 11.50 - 12.05 |
52-week range | 7.58 - 21.50 |
Volume | |
Avg. volume | 14,114 |
Market cap | 151.352M |
Beta (5Y monthly) | 3.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.70 |
Earnings date | 19 Oct 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximatel
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...